Immunitybio Inc Cash Flow-to-Debt Ratio
Immunitybio Inc cash flow-to-debt ratio. Immunitybio Inc (IBRX) has a Cash Flow-to-Debt Ratio of -0.12x as of September 2025, meaning its operating cash flow of $-68.91 Million could theoretically repay 0% of its total liabilities ($569.82 Million) in one year. See Immunitybio Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Immunitybio Inc (2013–2024)
Cash flow-to-debt ratio of Immunitybio Inc from 2013 to 2024. Historical debt coverage capacity for Immunitybio Inc across 12 annual periods. See debt-free asset ratio of Immunitybio Inc to measure how much of total assets are equity-financed.
Immunitybio Inc Cash Flow-to-Debt Ratio by Year (2013–2024)
Immunitybio Inc cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for Immunitybio Inc. For the full cash flow conversion analysis, see IBRX cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.45x | $-391.24 Million | $871.06 Million | ▼ -33.5% |
| 2023 | -0.34x | $-366.76 Million | $1.09 Billion | ▲ +19.1% |
| 2022 | -0.42x | $-337.51 Million | $812.18 Million | ▼ -7.9% |
| 2021 | -0.38x | $-274.42 Million | $712.82 Million | ▲ +23.8% |
| 2020 | -0.51x | $-171.72 Million | $339.87 Million | ▲ +92.5% |
| 2019 | -6.78x | $-152.11 Million | $22.44 Million | ▼ -284.3% |
| 2018 | -1.76x | $-63.38 Million | $35.94 Million | ▼ -14.2% |
| 2017 | -1.54x | $-48.78 Million | $31.60 Million | ▲ +3.7% |
| 2016 | -1.60x | $-38.59 Million | $24.08 Million | ▲ +31.3% |
| 2015 | -2.33x | $-25.30 Million | $10.85 Million | ▼ -4.7% |
| 2014 | -2.23x | $-5.35 Million | $2.40 Million | ▼ -1565.6% |
| 2013 | -0.13x | $-668.00K | $5.00 Million | — |